ATNX   $0.1873  -25.97% Market Closed

Athenex Inc
Last Events:

2023-07-18 Signal in Stochastic changed from bearish weakening to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: exit from the oversold zone.

2023-05-20 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-05-20 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the oversold territory and it heading south. These factors indicate that the downside potential still holds even though the market is oversold. Last signal: exit from the overbought zone.

2023-05-19 Signal in RSI changed from bearish recovery to bearish weakening. RSI indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: exit from the overbought zone.

2023-05-17 Signal in Stochastic changed from bearish weakening to bearish. The stochastic indicator is in the oversold territory and it heading north. These factors indicate that perhaps the downside trend is coming to an end. Last signal: entry into the oversold zone.

2023-05-16 Signal in Stochastic changed from bearish to bearish weakening. The stochastic indicator is in the oversold territory and it grows. These factors indicate that perhaps the downside trend is coming to an end. Last signal: main and signal line crossing.

2023-05-11 Signal in MACD changed from bearish weakening to bearish recovery. Oscillator MACD is in the negative territory it's higher than the signal line and falls. These factors mean that negative mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-05-11 Trend Power changed from medium strength to strong.


Current temperature: 1.64
ST: 0, Cor:

50-50 Year Forecast
Low with 50% probability: 0.12
Target: 2.50
High with 48% probability: 0.67
Analyst Recommendations:
Number of estimates 1
Target Price Mean 2.50
Mean unverified/preliminary 2.50 / 2.50
Target Price Low / High 2.50 / 2.50
Median / STD DEV 2.50 / 0.00
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Sell Sell Sell
rsi Sell Sell Sell
macd - - -
stoch - - -
ma20 - Sell Sell
ma50 Sell - -
ma100 Sell Sell -
Candlestick PatternMay 24, 2023 Doji - is formed when the open and the close are the same or very close. The body of candle is small. The length of the shadows are not important. The appearance of a Doji should alert the investor of major indecision.
ISIN US04685N1037
ceo Dr. Yiu-Nam Lau F.R.C.P., M.B.B.S., M.D., Ph.D.
Website https://www.athenex.com
Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through Oncology Innovation Platform and Commercial Platform segments. The company's Orascovery product candidates include Oral paclitaxel and encequidar for the treatment of metastatic breast cancer. It also offers Src Kinase product candidates comprising Tirbanibulin ointments for actinic keratosis, skin cancers, and psoriasis. In addition, the company engages in developing KUR-501, an autologous product that is in a phase I clinical trial for treating children with relapsed-refractory (R/R) high risk neuroblastoma; KUR-502, an allogeneic product for treating adults with R/R CD19 positive malignancies, including B cell lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia; and KUR-503, an allogeneic product that is in preclinical development for advanced hepatocellular carcinoma. Further, it engages in developing dual absorption enhancers to inhibit the P-gp transporter and the cytochrome p450 3A enzymes within the gastrointestinal tract; and has a portfolio of TCRs that recognize hotspot mutations in p53, KRAS, and EGFR genes for multiple tumors. The company was formerly known as Kinex Pharmaceuticals LLC and changed its name to Athenex, Inc. in August 2015. Athenex, Inc. was incorporated in 2003 and is headquartered in Buffalo, New York. On May 14, 2023, Athenex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.